A large team of researchers led by Wouter Karthaus, head of the Endocrine Therapy Resistance and Molecular Genetics Lab at EPFL, and Eneda Toska at Johns Hopkins University have identified the enzyme ...

Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, researchers are using the same tactics to advance prostate cancer treatment.

Experts project the diagnosis of over 300,000 prostate cancer cases in the United States in 2006, along with over 30,000 ...

Three recently-discovered molecular subtypes may help in crafting a more personalized treatment plan for men with prostate cancer. There are three distinct molecular subtypes of primary prostate ...

Among prostate cancer patients with a luminal B subtype, the 5-year biochemical progression-free survival rate was 72% in the apalutamide group and 54% in the placebo group. Recurrent prostate cancer ...